神经发育障碍和小头症:细胞亡,细胞循环,tau和粉样β前体蛋白如何APPly
Deborah K Sokol1, Debomoy K Lahiri2,3
1Section of Pediatrics, Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, United States.
Frontiers in molecular neuroscience
|October 9, 2023
概括
自闭症谱系障碍 (ASD) 和阿尔茨海默病有共同的联系. 氨基-β可以通过破坏神经发生和细胞循环,导致ASD的小头症.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 发展生物学 发展生物学
背景情况:
- 新兴研究强调了自闭症谱系障碍 (ASD) 和阿尔茨海默病之间的交叉关系.
- 研究报告指出,在患有自闭症的个体中,粉样蛋白-β前体蛋白 (APP) 和粉样蛋白-β (Aβ) 的水平发生变化.
- 与典型发育相比,在ASD中观察到的小头的频率更高.
研究的目的:
- 探索Aβ在ASD中获得的小头症中的Aβ的拟议作用.
- 检查Aβ可能影响神经发育和细胞周期进展的机制,导致小头症.
- 审查Aβ,小头症和ASD之间的关联,在像Trisomy 21 (唐氏综合征) 和其他神经发育障碍等条件下.
主要方法:
- 关于ASD,阿尔茨海默氏症和小头症的现有文献的综述.
- 对报告ASD中APP和Aβ水平的研究进行分析.
- 检查拟议的分子机制,将Aβ与神经发生和细胞循环中断联系起来.
主要成果:
- 在ASD儿童的血和脑组织中发现了APP和分泌的APP-alpha (sAPPα) 的升高水平以及Aβ40和Aβ42的降低水平.
- 假设Aβ可以通过破坏神经发生和细胞循环调节来促进ASD中的小头症.
- 21 号染色体上的 APP 基因与 21 号体中过多的 Aβ 相关,这与小头症和某些形式的 ASD 相关.
结论:
- Aβ代表了将ASD与获得的小头症联系在一起的潜在机制.
- 了解这些分子通路可能会为神经发育障碍提供见解,包括ASD和小头症.
- 进一步研究Aβ在Trisomy 21,dup 15q11.2-q13,Angelman和Rett综合征等疾病中的作用是有必要的.
相关概念视频
Alzheimer's Disease: Overview
506
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
506
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K


